FDA approves Janssen’s Xarelto for blood clot prevention
October 15, 2019Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
Reata reports top-line data for omaveloxolone in Freidreich’s ataxia
October 15, 2019Manufacturing and Production
Reata has reported that Part 2 of its mid-stage MOXIe trial of its Nrf2 activator omaveloxolone met its primary endpoint. …
Medical cannabis: On to greener pastures?
October 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medical cannabis, medicinal cannabis, pharma
In the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis
October 14, 2019Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma
Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …
Daiichi Sankyo show low CV events and bleeding in NVAF patients on Lixiana
October 14, 2019Sales and Marketing
Daiichi Sankyo have announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients treated with …
Shionogi reports positive results for cefiderocol in pneumonia
October 14, 2019Sales and Marketing
Shionogi has reported positive data from a trial of its investigational antibiotic cefiderocol which is already under regulatory review in …
Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris
October 14, 2019Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma
Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
Three focus areas to accelerate breakthrough drugs to market
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva
The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
Biotechnology Innovation Organization Chief to step down after US 2020 elections
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma
The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
Top Ten most popular articles on Pharmafile.com this week
October 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s the end of the week and time for a rundown of our top most popular articles on Pharmafile these …
AbbVie set to receive $330m after exiting Reata deal
October 11, 2019Medical Communications
AbbVie is to receive $330 million after Reata Pharmaceuticals reacquired development, manufacturing and commercialisation rights to a portfolio of Nrf2 …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
Neurolign secures eye diagnostic tech from Neuro Kinetics
October 11, 2019Medical Communications
Neurolign Technologies has acquired US-based eye diagnostic technology firm Neuro Kinetics for an undisclosed sum. Neuro Kinetics is based in …
Bayer UK unveils new Artificial Intelligence ‘LifeHub’
October 10, 2019Research and Development
Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease …
NICE recommends pentosan polysulfate sodium for NHS treatment of bladder pain syndrome
October 10, 2019Sales and Marketing NHS, NICE, bladder pain syndrome, pentosan polysulfate sodium
NICE has chosen to recommend pentosan polysulfate sodium, it has emerged, for use on the NHS in the treatment of …
Novo Nordisk enters into haemophilia gene therapy collaboration
October 10, 2019Research and Development
Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in …
Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
UCB Pharma to acquire Ra Pharmaceuticals in deal valued at $2.1bn
October 10, 2019Sales and Marketing
UCB has agreed to acquire US-based Ra Pharmaceuticals for $2.1 billion in a deal that will enable the Belgian drug …
The Lung Ambition Alliance: Stronger together
October 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma
Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture
October 9, 2019Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma
The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
